Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsPreferred Shares IssuedProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Valion Bio (TIVC) Gross Profit (2021 - 2025)

Valion Bio has reported Gross Profit over the past 5 years, most recently at -$145000.0 for Q3 2025.

  • For Q3 2025, Gross Profit fell 429.55% year-over-year to -$145000.0; the TTM value through Sep 2025 reached -$280000.0, down 213.82%, while the annual FY2024 figure was $2000.0, 99.3% down from the prior year.
  • Gross Profit for Q3 2025 was -$145000.0 at Valion Bio, down from $54000.0 in the prior quarter.
  • Over five years, Gross Profit peaked at $167000.0 in Q1 2024 and troughed at -$239000.0 in Q4 2024.
  • A 5-year average of $26842.1 and a median of $44000.0 in 2024 define the central range for Gross Profit.
  • Biggest five-year swings in Gross Profit: surged 2250.0% in 2022 and later plummeted 4880.0% in 2024.
  • Year by year, Gross Profit stood at -$2000.0 in 2021, then surged by 2250.0% to $43000.0 in 2022, then crashed by 88.37% to $5000.0 in 2023, then plummeted by 4880.0% to -$239000.0 in 2024, then surged by 39.33% to -$145000.0 in 2025.
  • Business Quant data shows Gross Profit for TIVC at -$145000.0 in Q3 2025, $54000.0 in Q2 2025, and $50000.0 in Q1 2025.